ALTEOGEN Inc.
14Patents
14Active
14Granted
47Portfolio score
Filing activity: Apr 22, 2010 → Dec 14, 2021
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9982032B2 | Stable liquid formulation of fusion protein with IgG Fc domain | Chemistry; Metallurgy | 11 | Active |
| US9814782B2 | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same | Chemistry; Metallurgy | 7 | Active |
| US9474803B2 | Composition for stabilizing fusion protein in which protein and FC domain are fused | Chemistry; Metallurgy | 4 | Active |
| US9012606B2 | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same | Chemistry; Metallurgy | 4 | Active |
| US9051395B2 | Alpha-1 antitrypsin variant, preparation method thereof and use thereof | Chemistry; Metallurgy | 1 | Active |
| US11235065B2 | Antibody-drug conjugate comprising modified antibody | Chemistry; Metallurgy | 1 | Active |
| US9902753B2 | Method of purifying a long-acting human growth hormone | Chemistry; Metallurgy | 0 | Active |
| US12371683B2 | Hyaluronidase variants and pharmaceutical composition comprising the same | Chemistry; Metallurgy | 0 | Active |
| US11981719B2 | Growth hormone receptor antagonists and fusion proteins thereof | Chemistry; Metallurgy | 0 | Active |
| US11866492B2 | Antibody specifically binding to FOLR1 and uses thereof | Physics | 0 | Active |
| US9821059B2 | Composition for stabilizing protein and pharmaceutical formulation comprising the same | Chemistry; Metallurgy | 0 | Active |
| US12090210B2 | Antibody-drug conjugate comprising modified antibody | Chemistry; Metallurgy | 0 | Active |
| US12221638B2 | Method for producing recombinant hyaluronidase | Chemistry; Metallurgy | 0 | Active |
| US11414476B2 | Method for producing fusion protein having IgG Fc domain | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.